CD30 expression in peripheral T-cell lymphomas
- 28 May 2013
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 98 (8), e81-e82
- https://doi.org/10.3324/haematol.2013.084913
Abstract
CD30 antigen is a trans-membrane glycoprotein belonging to the tumor necrosis factor receptor superfamily.[1][1] Upon stimulation, CD30 exerts pleiotropic effects on cell growth and survival, which largely depend on the NF-κB pathway activation.[2][2] In normal or inflamed tissues, CD30 expressionKeywords
This publication has 15 references indexed in Scilit:
- Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK centerHaematologica, 2012
- Distinct Motifs in the Intracellular Domain of Human CD30 Differentially Activate Canonical and Alternative Transcription Factor NF-κB SignalingPLOS ONE, 2012
- Extranodal NK/T-cell Lymphoma, Nasal Type, Includes Cases of Natural Killer Cell and αβ, γδ, and αβ/γδ T-cell OriginThe American Journal of Surgical Pathology, 2012
- Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 casesBlood, 2012
- CD30+ Neoplasms of the SkinCurrent Hematologic Malignancy Reports, 2011
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasThe New England Journal of Medicine, 2010
- Large CD30‐positive cells in benign, atypical lymphoid infiltrates of the skinJournal of Cutaneous Pathology, 2008
- Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic ScoreJournal of Clinical Oncology, 2006
- CD30 in Normal and Neoplastic CellsClinical Immunology, 1999
- Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxinThe Lancet, 1992